Lupin Arm Acquires UK-Based Renascience Pharma for ₹135 Crore

Lupin Limited announced that its UK arm, Lupin Healthcare (UK) Ltd, has acquired a 100% stake in Renascience Pharma Limited. The deal is valued at £12.3 million, which is approximately ₹135 crore. Following the transaction, Renascience will operate as a wholly-owned subsidiary of Lupin Healthcare (UK).

As of 10:54 am on April 3, Lupin shares price was trading at ₹2083.60, a 3.68% up for the day, despite being down 7.84% over the past six months and up 25.35% over the past year.

Renascience’s Product Portfolio

Renascience Pharma is a UK-based pharmaceutical company with a portfolio of 4 specialty products. These include:

• Branded injectable cephalosporins are used to treat infectious diseases
• A topical treatment for ear pain
• A branded quinazoline-like diuretic used in cardiovascular and renal conditions

These products are currently available in the UK market and are positioned in therapeutic areas that address specific treatment needs.

Lupin’s Existing UK Business

Lupin has an established presence in the UK through its branded business, offering medicines across various therapeutic segments. The acquisition of Renascience is expected to integrate these new products into its UK portfolio.

Statements from the Companies

According to a statement issued by Lupin, the acquisition is intended to support the company’s branded product offerings in the UK. Renascience will now trade under Lupin Healthcare (UK) Ltd.

Eric Che, Co-founder and Director of Renascience, noted that the deal enables the company to continue its existing operations and reach a wider patient base under new ownership.

Conclusion

Lupin Healthcare (UK) Ltd’s acquisition of Renascience Pharma provides it with complete ownership of a set of UK-based pharmaceutical products. These additions will now be managed under Lupin’s existing operations in the region. The deal is valued at £12.3 million and is another expansion of Lupin’s international business.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.